Moreover, Resistin increases breast cancer metastasis potential through induction epithelial to mesenchymal transition, a process in which cancer cells lose their epithelial characteristics and gain mesenchymal-like features, and that these effects may be associated with CAP1 (Avtanski et al., 2019). This evidence concerns the gene CAP1 and breast cancer.